Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for folic acid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
High dose of maternal folicacid supplementation is associated to infant asthma. Maternal folicacid supplementation had a positive effect on preventing neural tube defects (NTDs), but its effects in infant asthma remained unclear. A hospital-based case-control study was conducted with outpatients between March 2010 and March 2011 including 150 onset infant asthma cases and 212 controls, together with a meta-analysis involving 14,438 participants, was performed. The association between maternal (...) folicacid supplementation and the risk of infant asthma was not significant either in the meta-analysis (OR = 1.06, 95% CI =0.99-1.14) or in the case-control study (OR = 0.72, 95% CI =0.37-1.39). However, quantitative analysis of the supplementation dose demonstrated that the risk of infant asthma significantly increased for the infants whose mother were with high-dose supplementation (>72,000 µg•d; OR = 3.16, 95% CI =1.15-8.71) after adjusting for confounding factors in the case-control study
Pre-conception FolicAcid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other FolicAcid-Sensitive Congenital Anomalies Pre-conception FolicAcid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other FolicAcid-Sensitive Congenital Anomalies - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 37, Issue 6, Pages 534 (...) –549 Pre-conception FolicAcid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other FolicAcid-Sensitive Congenital Anomalies PRINCIPAL AUTHOR, x R. Douglas Wilson , MD Calgary AB x GENETICS COMMITTEE x R. Douglas Wilson , MD (Chair) x R. Douglas Wilson , x François Audibert , MD x François Audibert , x Jo-Ann Brock , MD x Jo-Ann Brock , x June Carroll , MD x June Carroll , x Lola Cartier , MSc x Lola Cartier , x Alain Gagnon , MD x Alain Gagnon
Effect of Maternal Multiple Micronutrient vs Iron-FolicAcid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh: The JiVitA-3 Randomized Trial. Maternal micronutrient deficiencies may adversely affect fetal and infant health, yet there is insufficient evidence of effects on these outcomes to guide antenatal micronutrient supplementation in South Asia.To assess effects of antenatal multiple micronutrient vs iron-folicacid supplementation on 6-month infant (...) -folicacid alone, taken daily from early pregnancy to 12 weeks postpartum.The primary outcome was all-cause infant mortality through 6 months (180 days). Prespecified secondary outcomes in this analysis included stillbirth, preterm birth (<37 weeks), and low birth weight (<2500 g). To maintain overall significance of α = .05, a Bonferroni-corrected α = .01 was calculated to evaluate statistical significance of primary and 4 secondary risk outcomes (.05/5).Among the 22,405 pregnancies in the multiple
The effect of folate fortification on folicacid-based homocysteine-lowering intervention and stroke risk: a meta-analysis. Folate and vitamin B12 are two vital regulators in the metabolic process of homocysteine, which is a risk factor of atherothrombotic events. Low folate intake or low plasma folate concentration is associated with increased stroke risk. Previous randomized controlled trials presented discordant findings in the effect of folicacid supplementation-based homocysteine lowering (...) on stroke risk. The aim of the present review was to perform a meta-analysis of relevant randomized controlled trials to check the how different folate fortification status might affect the effects of folicacid supplementation in lowering homocysteine and reducing stroke risk.Relevant randomized controlled trials were identified through formal literature search. Homocysteine reduction was compared in subgroups stratified by folate fortification status. Relative risks with 95 % confidence intervals were
Folicacid supplementation with and without vitamin B6 and revascularization risk: a meta-analysis of randomized controlled trials. There is a growing amount of data and a continuing controversy over the effect of folicacid supplementation with and without vitamin B6 on revascularization risk.We conducted a meta-analysis based on up-to-date published relevant randomized trials to further examine this issue. Relative risk (RR) was used to measure the effect of folicacid supplementation on risk (...) of revascularization using a random-effects model. Total revascularization was defined as any arterial revascularization. Restenosis was defined as stenosis of more than 50 percent of the luminal diameter.Overall, folicacid supplementation had no significant effect on coronary revascularization (9 trials, n = 27,418, RR = 0.99; 95%CI:0.88-1.11, P = 0.88), coronary artery bypass grafting (CABG) (5 trials, n = 10,703, 0.90; 0.79-1.03, P = 0.11), percutaneous coronary intervention (PCI) (5 trials, n = 10,703, 1.05
The effect of homocysteine-lowering therapy with folicacid on flow-mediated vasodilation in patients with coronary artery disease: a meta-analysis of randomized controlled trials. High level of homocysteine induces injury of endothelial cells and predicts adverse cardiovascular events. The objective was to assess the effect of homocysteine-lowering therapy with folicacid on flow-mediated vasodilation in patients with coronary artery disease.We conducted a meta-analysis of randomized (...) controlled trials identified from PubMed, Embase, the Cochrane Library. Eight studies were included. Homocysteine-lowering therapy with folicacid in patients with coronary artery disease significantly improve FMD as compared with placebo using random-effect model (SMD = 1.65 with 95% CI 1.12-2.17, p < 0.001). Subgroup analysis of subjects revealed that lipid-lowering therapy, study duration, and Delphi criteria had no effects on FMD.Our meta-analysis demonstrated that folicacid supplementation can
FolicAcid USE OF FOLICACID IN PREGNANCY 0344 892 0909 USE OF FOLICACID IN PREGNANCY (Date of issue: February 2018 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Folicacid (pteroylglutamic acid/PGA) is a synthetic derivative (...) of the water-soluble form of vitamin B9 (also known as folate). It requires metabolism to dihydrofolic acid and then to its biologically active form tetrahydrofolate. Folate is necessary for the production of blood cells and DNA. Folicacid is used in the treatment of nutritional megaloblastic anaemias and prophylactically in individuals at risk of deficiency e.g. due to chronic haemolysis or renal dialysis. During pregnancy folate requirements are increased 5- to 10-fold and pregnant women are therefore
Efficacy of folicacid supplementation on endothelial function and plasma homocysteine concentration in coronary artery disease: A meta-analysis of randomized controlled trials. The aim of the present study was to conduct an updated meta-analysis of relevant randomized controlled trials (RCTs) in order to estimate the effect of folicacid supplementation on endothelial function and the concentration of plasma homocysteine in patients with coronary artery disease (CAD). An extensive search (...) of PubMed was conducted to identify RCTs that compared folicacid with placebo therapy. The mean difference (MD) and 95% confidence interval (CI) were used as a measure of the correlation between folicacid supplementation and endothelial function/plasma homocysteine concentration. Of the 377 patients included in this analysis, 191 patients underwent folicacid supplementation and 186 individuals underwent placebo treatment. Compared with the use of a placebo, folicacid supplementation alone exhibited
Effectiveness of folicacid supplementation in pregnancy on reducing the risk of small-for-gestational age neonates: a population study, systematic review and meta-analysis To assess the effect of timing of folicacid (FA) supplementation during pregnancy on the risk of the neonate being small for gestational age (SGA).A population database study and a systematic review with meta-analysis including the results of this population study.A UK regional database was used for the population study
FolicAcid Supplementation and Preterm Birth: Results from Observational Studies. Folicacid (FA) supplementation is recommended worldwide in the periconceptional period for the prevention of neural tube defects. Due to its involvement in a number of cellular processes, its role in other pregnancy outcomes such as miscarriage, recurrent miscarriage, low birth weight, preterm birth (PTB), preeclampsia, abruptio placentae, and stillbirth has been investigated. PTB is a leading cause of perinatal
Biomarker responses to folicacid intervention in healthy adults: a meta-analysis of randomized controlled trials. The task of revising dietary folate recommendations for optimal health is complicated by a lack of data quantifying the biomarker response that reliably reflects a given folate intake.We conducted a dose-response meta-analysis in healthy adults to quantify the typical response of recognized folate biomarkers to a change in folicacid intake.Electronic and bibliographic searches (...) identified 19 randomized controlled trials that supplemented with folicacid and measured folate biomarkers before and after the intervention in apparently healthy adults aged ≥18 y. For each biomarker response, the regression coefficient (β) for individual studies and the overall pooled β were calculated by using random-effects meta-analysis.Folate biomarkers (serum/plasma and red blood cell folate) increased in response to folicacid in a dose-response manner only up to an intake of 400 μg/d
Efficacy of folicacid supplementation in stroke prevention: new insight from a meta-analysis. There are growing data and a continuing controversy over the efficacy of folicacid supplementation in stroke prevention. We conducted a meta-analysis based on relevant, up-to-date published randomised trials to further examine this issue. Relative risk (RR) was used to measure the effect of folicacid supplementation on risk of stroke with a fixed-effects model. Overall, folicacid (...) supplementation reduced the risk of stroke by 8% (n = 55,764; RR: 0.92; 95% CI: 0.86-1.00, p = 0.038). In the 10 trials with no or partial folicacid fortification (n = 43,426), the risk of stroke was reduced by 11% (0.89; 0.82-0.97, p = 0.010). Within these trials, a greater beneficial effect was observed among trials with a lower percent use of statins [≤ 80% (median); 0.77; 0.64-0.92, p = 0.005], and a meta-regression analysis also suggested a positive dose-response relationship between percent use
[Folicacid supplementation and colorrectal adenoma recurrence: systematic review]. Observational studies show that folate levels may be associated with the development of adenomas and colorectal cancer, suggesting that folicacid supplementation may have a preventive effect.Systematic review of scientific evidence from randomized placebo-controlled clinical studies to identify the effects of folicacid supplementation on the recurrence of colorectal adenomas.Medline via Pubmed systematic (...) review of randomized clinical trials, double-blind and placebo-controlled and references, specifically to evaluate the effect of acid supplementation on the recurrence of colorectal adenomas.Seven randomized clinical trials that met the inclusion criteria were selected and evaluated for analysis based on pre established criteria.The selected studies do not support that folicacid supplementation is beneficial in recurrence of colorectal adenomas. We observed in some studies differences in risk
Prenatal folicacid and risk of asthma in children: a systematic review and meta-analysis. Childhood asthma has become a critical public health problem because of its high morbidity and increasing prevalence. The impact of nutrition and other exposures during pregnancy on long-term health and development of children has been of increasing interest.We performed a systematic review and meta-analysis of the association of folate and folicacid intake during pregnancy and risk of asthma and other (...) allergic outcomes in children.We performed a systematic search of 8 electronic databases for articles that examined the association between prenatal folate or folicacid exposure and risk of asthma and other allergic outcomes (eg, allergy, eczema, and atopic dermatitis) in childhood. We performed a meta-analysis by using a random-effects model to derive a summary risk estimate of studies with similar exposure timing, exposure assessment, and outcomes.Our meta-analysis provided no evidence
Homocysteine-lowering therapy with folicacid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. The efficacy of homocysteine-lowering therapy with folicacid to lower homocysteine levels in an effort to reduce cardiovascular disease (CVD) risk in patients with kidney disease remains inconclusive. We conducted a meta-analysis of relevant randomized trials to further examine this issue.This meta-analysis included (...) 8234 patients with kidney disease from nine qualified randomized trials using folicacid therapy, and with CVD reported as one of the endpoints. Relative risk (RR) was used to measure the effect of folicacid supplementation on risk of CVD using a random effects model.When pooling the nine randomized trials, folicacid therapy reduced the risk of CVD by 10%（RR = 0.90; 95% CI:0.81-1.00, P = 0.046). A greater beneficial effect was observed among those trials without a history of grain fortification
Folicacid supplementation use and the MTHFR C677T polymorphism in orofacial clefts etiology: An individual participant data pooled-analysis. This study examines gene-environment interaction between the MTHFR C667T polymorphism and folicacid in the etiology of orofacial clefts (OFC). We used a pooled-analytical approach on four studies that used similar methods.We used logistic regression to analyze the pooled sample of 1149 isolated cases and 1161 controls. Fetal and maternal MTHFR C677T (...) genotypes, and maternal periconceptional exposure to smoking, alcohol, vitamin containing folicacid and folicacid supplements were contrasted between the cleft types [non-syndromic clefts lip or without cleft palate (CL(P)) and non-syndromic cleft palate (CP)] and control groups.There was a reduced risk of CL(P) with maternal folicacid use (p = 0.008; OR = 0.70, 95% CI: 0.65-0.94) and with supplements containing folicacid (p = 0.028, OR = 0.80, 95% CI: 0.65-0.94). Maternal smoking increased the risk
Knowledge and periconceptional use of folicacid for the prevention of neural tube defects in ethnic communities in the United Kingdom: systematic review and meta-analysis. It is widely accepted that periconceptional supplementation with folicacid can prevent a significant proportion of neural tube defects (NTDs). The present study evaluated how folicacid knowledge and periconceptional use for NTD prevention varies by ethnicity in the United Kingdom (U.K.).A literature search was conducted (...) to identify studies that included assessment of folicacid knowledge or use in U.K. women of different ethnicities. Only research and referenced sources published after 1991, the year of the landmark Medical Research Council's Vitamin Study, were included. A meta-analysis was performed of studies that assessed preconceptional folicacid use in Caucasians and non-Caucasians.Five studies met the inclusion criteria for assessment of knowledge and/or use of folicacid supplements in U.K. women including non
Folicacid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folicacid metabolism. Many patients treated with MTX experience mucosal, gastrointestinal, hepatic or haematologic side effects. Supplementation with folic (...) or folinic acid during treatment with MTX may ameliorate these side effects.To identify trials of supplementation with folicacid or folinic acid during MTX therapy for rheumatoid arthritis and to assess the benefits and harms of folicacid and folinic acid (a) in reducing the mucosal, gastrointestinal (GI), hepatic and haematologic side effects of MTX, and (b) whether or not folic or folinic acid supplementation has any effect on MTX benefit.We originally performed MEDLINE searches, from January 1966
Impact of folicacid fortification of flour on neural tube defects: a systematic review. To review the impact of folicacid fortification of flour on the prevalence of neural tube defects (NTD).Systematic review of the literature on MEDLINE via PubMed, Scopus, OvidSP and LILACS (Latin American and Caribbean Health Sciences Literature) reporting the impact of folicacid fortification of flour on the prevalence of NTD in 2000-2011. Focusing on Santiago of Chile's birth defects registry (1999-2009 (...) ) and the monitoring of flour fortification, we analysed the prevalence (NTD cases/10 000 births) pre and post flour fortification and the percentile distribution of folicacid content in flour (2005-2009). We explored the potential association between median folicacid in flour (mg/kg) and the prevalence of NTD.Chile, Argentina, Brazil, Canada, Costa Rica, Iran, Jordan, South Africa and the USA.Live births and stillbirths.Twenty-seven studies that met inclusion criteria were evaluated. Costa Rica showed
Effects of folicacid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Some countries fortify flour with folicacid to prevent neural tube defects but others do not, partly because of concerns about possible cancer risks. We aimed to assess any effects on site-specific cancer rates in the randomised trials of folicacid supplementation, at doses higher than those from fortification.In these meta-analyses, we (...) sought all trials completed before 2011 that compared folicacid versus placebo, had scheduled treatment duration at least 1 year, included at least 500 participants, and recorded data on cancer incidence. We obtained individual participant datasets that included 49,621 participants in all 13 such trials (ten trials of folicacid for prevention of cardiovascular disease [n=46,969] and three trials in patients with colorectal adenoma [n=2652]). All these trials were evenly randomised. The main outcome